Lineage Cell Therapeutics, Inc.

NYSEAM:LCTX 株式レポート

時価総額:US$154.1m

Lineage Cell Therapeutics 過去の業績

過去 基準チェック /06

Lineage Cell Therapeutics's earnings have been declining at an average annual rate of -4.5%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 29% per year.

主要情報

-4.5%

収益成長率

-1.3%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率29.0%
株主資本利益率-36.2%
ネット・マージン-391.0%
前回の決算情報30 Jun 2024

最近の業績更新

Recent updates

What Type Of Shareholders Own The Most Number of Lineage Cell Therapeutics, Inc. (NYSEMKT:LCTX) Shares?

Feb 17
What Type Of Shareholders Own The Most Number of Lineage Cell Therapeutics, Inc. (NYSEMKT:LCTX) Shares?

If You Had Bought Lineage Cell Therapeutics (NYSEMKT:LCTX) Stock A Year Ago, You Could Pocket A 129% Gain Today

Dec 26
If You Had Bought Lineage Cell Therapeutics (NYSEMKT:LCTX) Stock A Year Ago, You Could Pocket A 129% Gain Today

収支内訳

Lineage Cell Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NYSEAM:LCTX 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Jun 246-241416
31 Mar 248-241416
31 Dec 239-211416
30 Sep 239-23178
30 Jun 2311-22188
31 Mar 2312-241911
31 Dec 2215-262314
30 Sep 2214-492335
30 Jun 2213-512334
31 Mar 229-492334
31 Dec 214-431834
30 Sep 214-121712
30 Jun 212-121612
31 Mar 212-141512
31 Dec 202-211612
30 Sep 203-271613
30 Jun 203-361714
31 Mar 203-591816
31 Dec 194-121918
30 Sep 193-522218
30 Jun 193312419
31 Mar 195572420
31 Dec 185-462521
30 Sep 185-732322
30 Jun 186-1252224
31 Mar 184-1332123
31 Dec 173-202024
30 Sep 174471926
30 Jun 173641926
31 Mar 1741002229
31 Dec 166342836
30 Sep 166253342
30 Jun 167-203647
31 Mar 168-543647
31 Dec 157-472943
30 Sep 157-452441
30 Jun 156-392038
31 Mar 155-391938
31 Dec 145-361838
30 Sep 145-451735
30 Jun 145-461733
31 Mar 145-441630
31 Dec 134-441627

質の高い収益: LCTX is currently unprofitable.

利益率の向上: LCTX is currently unprofitable.


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: LCTX is unprofitable, and losses have increased over the past 5 years at a rate of 4.5% per year.

成長の加速: Unable to compare LCTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

収益対業界: LCTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


株主資本利益率

高いROE: LCTX has a negative Return on Equity (-36.19%), as it is currently unprofitable.


総資産利益率


使用総資本利益率


過去の好業績企業の発掘